[1]
|
Albert, C.M. and Ruskin, J.N. (2001) Risk Stratifiers for Sudden Cardiac Death (SCD) in the Community: Primary Pre-vention of SCD. Cardiovascular Research, 50, 186-196. https://doi.org/10.1016/S0008-6363(00)00319-9
|
[2]
|
Jouven, X., Desnos, M., Guerot, C., et al. (1999) Predicting Sudden Death in the Population: The Paris Prospective Study I. Circulation, 99, 1978-1983. https://doi.org/10.1161/01.CIR.99.15.1978
|
[3]
|
Maldonado, C., Soni, C.V., Todnem, N.D., et al. (2010) Hyper-homocysteinemia and Sudden Cardiac Death: Potential Arrhythmogenic Mechanisms. Current Vascular Pharmacology, 8, 64-74.
https://doi.org/10.2174/157016110790226552
|
[4]
|
Rosenberger, D., Gargoum, R., Tyagi, N., et al. (2011) Ho-mocysteine Enriched Diet Leads to Prolonged QT Interval and Reduced Left Ventricular Performance in Telemetric Mon-itored Mice. Nutrition, Metabolism and Cardiovascular Diseases, 21, 492-498. https://doi.org/10.1016/j.numecd.2009.11.014
|
[5]
|
Lipton, S.A., Kim, W.K., Choi, Y.B., et al. (1997) Neurotoxi-city Associated with Dual Actions of Homocysteine at the N-methyl-D-aspartate Receptor. Proceedings of the National Academy of Sciences of the United States of America, 94, 5923-5928. https://doi.org/10.1073/pnas.94.11.5923
|
[6]
|
Gill, S.S., Pulido, O.M., Mueller, R.W., et al. (1998) Molecular and Immunochemical Characterization of the Ionotropic Glutamate Receptors in the Rat Heart. Brain Research Bulletin, 46, 429-434.
https://doi.org/10.1016/S0361-9230(98)00012-4
|
[7]
|
Gill, S., Veinot, J., Kavanagh, M., et al. (2007) Human Heart Glutamate Receptors—Implications for Toxicology, Food Safety, and Drug Discovery. Toxicologic Pathology, 35, 411-417. https://doi.org/10.1080/01926230701230361
|
[8]
|
Mayer, M.L., Westbrook, G.L. and Guthrie, P.B. (1984) Voltage-Dependent Block by Mg2+ of NMDA Responses in Spinal Cord Neurones. Nature, 309, 261-263. https://doi.org/10.1038/309261a0
|
[9]
|
Harker, L.A., Harlan, J.M. and Ross, R. (1983) Effect of Sulfinpyrazone on Homocysteine-Induced Endothelial Injury and Arteriosclerosis in Baboons. Circulation Research, 53, 731-739. https://doi.org/10.1161/01.RES.53.6.731
|
[10]
|
Boushey, C.J., Beresford, S.A., Omenn, G.S., et al. (1995) A Quan-titative Assessment of Plasma Homocysteine as a Risk Factor for Vascular Disease. Probable Benefits of Increasing Folic Acid Intakes. JAMA, 274, 1049-1057.
https://doi.org/10.1001/jama.1995.03530130055028
|
[11]
|
Klerk, M., Verhoef, P., Clarke, R., et al. (2002) MTHFR 677C→T Polymorphism and Risk of Coronary Heart Disease: A Meta-Analysis. JAMA, 288, 2023-2031. https://doi.org/10.1001/jama.288.16.2023
|
[12]
|
(2005) Dose-Dependent Effects of Folic Acid on Blood Concentra-tions of Homocysteine: A Meta-Analysis of the Randomized Trials. The American Journal of Clinical Nutrition, 82, 806-812. https://doi.org/10.1093/ajcn/82.4.806
|
[13]
|
Li, Y., Huang, T., Zheng, Y., et al. (2016) Folic Acid Supple-mentation and the Risk of Cardiovascular Diseases: A Meta-Analysis of Randomized Controlled Trials. Journal of the American Heart Association, 5, e003768.
https://doi.org/10.1161/JAHA.116.003768
|
[14]
|
Arnesen, E., Refsum, H., Bønaa, K.H., et al. (1995) Serum Total Homocysteine and Coronary Heart Disease. International Journal of Epidemiology, 24, 704-709. https://doi.org/10.1093/ije/24.4.704
|
[15]
|
Nygård, O., Nordrehaug, J.E., Refsum, H., et al. (1997) Plasma Homo-cysteine Levels and Mortality in Patients with Coronary Artery Disease. The New England Journal of Medicine, 337, 230-236.
https://doi.org/10.1056/NEJM199707243370403
|
[16]
|
Wald, D.S., Law, M. and Morris, J.K. (2002) Homocysteine and Cardiovascular Disease: Evidence on Causality from a Meta-Analysis. BMJ, 325, 1202. https://doi.org/10.1136/bmj.325.7374.1202
|
[17]
|
Casas, J.P., Bautista, L.E., Smeeth, L., et al. (2005) Homocysteine and Stroke: Evidence on a Causal Link from Mendelian Randomisation. The Lancet, 365, 224-232. https://doi.org/10.1016/S0140-6736(05)70152-5
|
[18]
|
Robinson, K., Arheart, K., Refsum, H., et al. (1998) Low Circulating Folate and Vitamin B6 Concentrations: Risk Factors for Stroke, Peripheral Vascular Disease, and Coronary Artery Disease. Circulation, 97, 437-443.
https://doi.org/10.1161/01.CIR.97.5.437
|
[19]
|
Folsom, A.R., Nieto, F.J., McGovern, P.G., et al. (1998) Prospective Study of Coronary Heart Disease Incidence in Relation to Fasting Total Homocysteine, Related Genetic Polymorphisms, and B Vitamins: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation, 98, 204-210. https://doi.org/10.1161/01.CIR.98.3.204
|
[20]
|
Voutilainen, S., Rissanen, T.H., Virtanen, J., Lakka, T.A., et al. (2001) Low Dietary Folate Intake Is Associated with an Excess Incidence of Acute Coronary Events: The Kuopio Is-chemic Heart Disease Risk Factor Study. Circulation, 103, 2674-2680. https://doi.org/10.1161/01.CIR.103.22.2674
|
[21]
|
Jacques, P.F., Selhub, J., Bostom, A.G., et al. (1999) The Effect of Folic Acid Fortification on Plasma Folate and Total Homocysteine Concentrations. The New England Journal of Med-icine, 340, 1449-1454.
https://doi.org/10.1056/NEJM199905133401901
|
[22]
|
Liu, X.D, Shi, M., Xia, F., Han, J.L., et al. (2015) The Chi-na Stroke Secondary Prevention Trial (CSSPT) Protocol: A Double-Blinded, Randomized, Controlled Trial of Combined Folic Acid and B Vitamins for Secondary Prevention of Stroke. International Journal of Stroke, 10, 264-268. https://doi.org/10.1111/ijs.12017
|
[23]
|
Wald, N.J. and Law, M.R. (2003) A Strategy to Reduce Cardiovascular Disease by More than 80%. BMJ, 326, 1419.
https://doi.org/10.1136/bmj.326.7404.1419
|
[24]
|
Toole, J.F., Malinow, M.R., Chambless, L.E., et al. (2004) Low-ering Homocysteine in Patients with Ischemic Stroke to Prevent Recurrent Stroke, Myocardial Infarction, and Death: The Vitamin Intervention for Stroke Prevention (VISP) Randomized Controlled Trial. JAMA, 291, 565-575. https://doi.org/10.1001/jama.291.5.565
|
[25]
|
Jadad, A.R., Moore, R.A., Carroll, D., et al. (1996) Assessing the Quality of Reports of Randomized Clinical Trials: Is Blinding Necessary? Controlled Clinical Trials, 17, 1-12. https://doi.org/10.1016/0197-2456(95)00134-4
|
[26]
|
Albert, C.M., Cook, N.R., Gaziano, J.M., et al. (2008) Effect of Folic Acid and B Vitamins on Risk of Cardiovascular Events and Total Mortality among Women at High Risk for Cardiovascular Disease: A Randomized Trial. JAMA, 299, 2027-2036. https://doi.org/10.1001/jama.299.17.2027
|
[27]
|
Bønaa, K.H., Njølstad, I., Ueland, P.M., et al. (2006) Homocysteine Lowering and Cardiovascular Events after Acute Myocardial Infarction. The New England Journal of Medicine, 354, 1578-1588.
https://doi.org/10.1056/NEJMoa055227
|
[28]
|
Ebbing, M., Bleie, Ø., Ueland, P.M., et al. (2008) Mortality and Car-diovascular Events in Patients Treated with Homocysteine-Lowering B Vitamins after Coronary Angiography: A Ran-domized Controlled Trial. JAMA, 300, 795-804.
https://doi.org/10.1001/jama.300.7.795
|
[29]
|
Armitage, J.M., Bowman, L., Clarke, R.J., et al. (2010) Effects of Homocysteine-Lowering with Folic Acid Plus Vitamin B12 vs Placebo on Mortality and Major Morbidity in Myocardial Infarction Survivors: A Randomized Trial. JAMA, 303, 2486-2494. https://doi.org/10.1001/jama.2010.840
|
[30]
|
Liakishev, A.A. (2006) Homocysteine Lowering with Folic Acid and B Vitamins in Vascular Disease. Kardiologiia, 46, Article No. 70.
|
[31]
|
Galan, P., Kesse-Guyot, E., Czernichow, S., et al. (2010) Effects of B Vitamins and Omega 3 Fatty Acids on Cardiovascular Diseases: A Randomised Placebo Controlled Trial. BMJ, 341, c6273. https://doi.org/10.1136/bmj.c6273
|
[32]
|
Wang, L., Li, H., Zhou, Y., et al. (2015) Low-Dose B Vitamins Supplementation Ameliorates Cardiovascular Risk: A Double-Blind Randomized Controlled Trial in Healthy Chinese Elderly. European Journal of Nutrition, 54, 455-464.
https://doi.org/10.1007/s00394-014-0729-5
|
[33]
|
Homocysteine Studies Collaboration (2002) Homocysteine and Risk of Ischemic Heart Disease and Stroke: A Meta-Analysis. JAMA, 288, 2015-2022. https://doi.org/10.1001/jama.288.16.2015
|
[34]
|
Liem, A., Reynierse-Buitenwerf, G.H., Zwinderman, A.H., et al. (2003) Secondary Prevention with Folic Acid: Effects on Clinical Outcomes. Journal of the American College of Cardi-ology, 41, 2105-2113.
https://doi.org/10.1016/S0735-1097(03)00485-6
|
[35]
|
Liem, A.H., van Boven, A.J., Veeger, N.J., et al. (2004) Ef-ficacy of Folic Acid When Added to Statin Therapy in Patients with Hypercholesterolemia Following Acute Myocardial Infarction: A Randomised Pilot Trial. International Journal of Cardiology, 93, 175-179. https://doi.org/10.1016/j.ijcard.2003.02.001
|
[36]
|
Lonn, E., Held, C., Arnold, J.M., et al. (2006) Rationale, Design and Baseline Characteristics of a Large, Simple, Randomized Trial of Combined Folic Acid and Vitamins B6 and B12 in High-Risk Patients: The Heart Outcomes Prevention Evaluation (HOPE)-2 Trial. Canadian Journal of Cardiology, 22, 47-53.
https://doi.org/10.1016/S0828-282X(06)70238-0
|
[37]
|
Schnyder, G., Roffi, M., Pin, R., et al. (2001) Decreased Rate of Coronary Restenosis after Lowering of Plasma Homocysteine Levels. The New England Journal of Medicine, 345, 1593-1600. https://doi.org/10.1056/NEJMoa011364
|
[38]
|
Lange, H., Suryapranata, H., De Luca, G., et al. (2004) Folate Therapy and In-Stent Restenosis after Coronary Stenting. The New England Journal of Medicine, 350, 2673-2681. https://doi.org/10.1056/NEJMoa032845
|
[39]
|
Verhaar, M.C., Stroes, E. and Rabelink, T.J. (2002) Fo-lates and Cardiovascular Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 22, 6-13. https://doi.org/10.1161/hq0102.102190
|
[40]
|
van Dijk, R.A., Rauwerda, J.A., Steyn, M., et al. (2001) Long-Term Homocysteine-Lowering Treatment with Folic Acid Plus Pyridoxine Is Associated with Decreased Blood Pressure but Not with Improved Brachial Artery Endothelium-Dependent Vasodilation or Carotid Artery Stiffness: A 2-Year, Ran-domized, Placebo-Controlled Trial. Arteriosclerosis, Thrombosis, and Vascular Biology, 21, 2072-2079. https://doi.org/10.1161/hq1201.100223
|
[41]
|
Vermeulen, E.G., Stehouwer, C.D., Valk, J., et al. (2004) Effect of Homocysteine-Lowering Treatment with Folic Acid plus Vitamin B on Cerebrovascular Atherosclerosis and White Mat-ter Abnormalities as Determined by MRA and MRI: A Placebo-Controlled, Randomized Trial. European Journal of Clinical Investigation, 34, 256-261.
https://doi.org/10.1111/j.1365-2362.2004.01332.x
|
[42]
|
Stanger, O., Semmelrock, H.J., Wonisch, W., et al. (2002) Effects of Folate Treatment and Homocysteine Lowering on Resistance Vessel Reactivity in Atherosclerotic Subjects. Journal of Pharmacology and Experimental Therapeutics, 303, 158-162. https://doi.org/10.1124/jpet.102.036715
|
[43]
|
Durga, J., van Tits, L.J., Schouten, E.G., et al. (2005) Effect of Low-ering of Homocysteine Levels on Inflammatory Markers: A Randomized Controlled Trial. Archives of Internal Medicine, 165, 1388-1394.
https://doi.org/10.1001/archinte.165.12.1388
|
[44]
|
Thambyrajah, J., Landray, M.J., Jones, H.J., et al. (2001) A Randomized Double-Blind Placebo-Controlled Trial of the Effect of Homocysteine-Lowering Therapy with Folic Acid on Endothelial Function in Patients with Coronary Artery Disease. Journal of the American College of Cardiology, 37, 1858-1863.
https://doi.org/10.1016/S0735-1097(01)01235-9
|
[45]
|
Doshi, S.N., Moat, S.J., McDowell, I.F., et al. (2002) Low-ering Plasma Homocysteine with Folic Acid in Cardiovascular Disease: What Will the Trials Tell Us? Atherosclerosis, 165, 1-3.
https://doi.org/10.1016/S0021-9150(02)00191-0
|
[46]
|
Woodman, R.J., Celermajer, D.E., Thompson, P.L., et al. (2004) Folic Acid Does Not Improve Endothelial Function in Healthy Hyperhomocysteinaemic Subjects. Clinical Science (London), 106, 353-358.
https://doi.org/10.1042/CS20030296
|
[47]
|
Dusitanond, P., Eikelboom, J.W., Hankey, G.J., et al. (2005) Homocys-teine-Lowering Treatment with Folic Acid, Cobalamin, and Pyridoxine Does Not Reduce Blood Markers of Inflammation, Endothelial Dysfunction, or Hypercoagulability in Patients with Previous Transient Ischemic Attack or Stroke: A Ran-domized Substudy of the VITATOPS Trial. Stroke, 36, 144-146. https://doi.org/10.1161/01.STR.0000150494.91762.70
|
[48]
|
Stover, P.J. (2004) Physiology of Folate and Vitamin B12 in Health and Disease. Nutrition Reviews, 62, S3-S12; Discussion S13. https://doi.org/10.1301/nr.2004.jun.S3-S12
|
[49]
|
Matsubara, K., Mori, M., Akagi, R., et al. (2004) Anti-Angiogenic Effect of Pyridoxal 5’-Phosphate, Pyridoxal and Pyridoxamine on Embryoid Bodies Derived from Mouse Embryonic Stem Cells. International Journal of Molecular Medicine, 14, 819-823. https://doi.org/10.3892/ijmm.14.5.819
|